Feed BNTC
BN
Benitec Biopharma Inc. BNTC NASDAQ · Healthcare · United States
$9.04 -0.55% -$0.05
Summary
64 / 100 · Bulios Score
Valuation 93Growth 100Profitability -Quality 0Debt 100Stability 28
What speaks for it
- It holds more cash than debt: $180.0M against $762.0K.
- The price moves less than the market (beta 0.25).
What to watch
- It passes only 1 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapIs it growing?
Yes, fastRevenue (USD)
2022202320242025202620272028
Diluted EPS (USD)
2022202320242025202620272028
- Analyst estimate
There is not enough revenue history yet to say how fast it grows.
Growth in detailDoes it make money?
Over the last 12 months it made a loss of $45.5M.
Profitability in detailIs it financially healthy?
YesCash and short-term investments $180.0M
Debt $762.0K
Free cash flow over 12 months -$17.1M
Over the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 7
- Hold 1
- Sell 0
Today's price within the analysts' price targets
Today's price $9.04 Average target $21
$9.04 $25
The average target of $21 is 132% above today's price. 88% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2023By product
- License 100%
By region
- AUSTRALIA 100%
License brings in 100% of revenue.
Segments in detail